Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

Vipawee S. Chata Medical College of Georgia at Augusta University, Augusta, GA, USA

https://orcid.org/0000-0002-8012-1974

Donovan G. Kearnsb Loma Linda School of Medicine, Loma Linda, CA, USA

Shelley K. Uppalc Albany Medical College, Albany, NY, USA

Jashin J. Wud Dermatology Research, Education Foundation, Irvine, CA, USACorrespondence[email protected]

"Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy." Journal of Dermatological Treatment, 32(5), pp. 495–496

Disclosure statement

Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis; a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy's Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, and UCB, Valeant Pharmaceuticals North America LLC; and a speaker for AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC. The other coauthors do not have any conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

Information for

Open access

Opportunities

Help and information

Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature